SequelSEC

LIFECORE BIOMEDICAL, INC. \DE\ LFCR

Pharmaceutical Preparations · CIK 0001005286 · Fiscal year ends 0525

AnnualQuarterlyTTM
Revenue
$34.17M
Fiscal year ended 2026-06-30
Operating income
$2.57M
Fiscal year ended 2026-06-30
Free cash flow
-$2.70M
Fiscal year ended 2026-06-30

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported revenue of $34.17M and net income of -$6.16M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from LIFECORE BIOMEDICAL, INC. \DE\’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

LIFECORE BIOMEDICAL, INC. \DE\ income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-09-302025-05-252025-02-232024-11-242024-08-252024-05-262024-02-252023-11-26
Revenue$34.17M$23.19M$31.11M$36.44MUnavailable$32.56M$24.70M$37.89M$35.70M$30.15M
Cost of revenue$22.09M$18.73M$23.32M$22.46MUnavailable$21.48M$19.32M$20.61M$23.81M$20.19M
Gross profit$12.08M$4.46M$7.79M$13.98MUnavailable$11.08M$5.39M$17.27M$11.89M$9.96M
Operating income$2.57M-$4.67M-$3.07M$5.33MUnavailable-$1.96M-$11.58M$2.15M-$895.00K-$1.48M
Net income-$6.16M-$14.98M-$9.99M-$1.15MUnavailable-$6.57M-$16.23M-$7.08M$15.63M$14.22M
Research & development$1.54M$1.22M$1.96M$2.10MUnavailable$1.92M$2.19M$2.16M$2.17M$2.10M
Weighted-average diluted sharesshares 37.57Mshares 37.48Mshares 37.40Mshares 37.01MUnavailableshares 34.36Mshares 30.86MUnavailableshares 36.61Mshares 36.42M
Pretax income-$6.13M-$14.94M-$9.66M-$1.11MUnavailable-$6.53M-$16.26M-$7.14M$15.00M$14.18M
Income tax expense$23.00K$43.00K$333.00K$33.00KUnavailable$43.00K-$25.00K-$57.00K$217.00K-$65.00K
Diluted EPS$-0.19$-0.43$-0.29$-0.06Unavailable$-0.25$-0.53Unavailable$0.42$0.39
Selling, general & administrative$7.97M$7.92M$8.90M$8.98MUnavailable$11.12M$14.78M$12.23M$9.85M$9.34M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

LIFECORE BIOMEDICAL, INC. \DE\ balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-09-302025-05-252025-02-232024-11-242024-08-252024-05-262024-02-252023-11-26
Cash & equivalents$17.24M$20.80M$18.86M$8.26MUnavailable$9.46MUnavailable$8.46MUnavailableUnavailable
Total assets$229.50M$225.50M$235.20M$239.34MUnavailable$255.39M$246.82M$253.96M$246.24M$245.82M
Current assets$83.69M$77.64M$83.93M$85.68MUnavailable$81.86M$74.18M$81.03M$76.16M$76.71M
Total liabilities$213.41M$204.72M$198.42M$191.91MUnavailable$195.63M$207.32M$200.06M$186.81M$203.47M
Current liabilities$21.64M$20.50M$29.96M$30.18MUnavailable$35.29M$40.52M$38.87M$36.81M$40.25M
Total equity incl. NCI-$34.09M-$28.44M-$10.54M$1.34MUnavailable$15.45M-$3.94M$11.32M$17.69M$1.42M
Temporary (mezzanine) equity$50.19M$49.22M$47.32M$46.10MUnavailable$44.31M$43.44M$42.59M$41.75M$40.92M
Inventory$25.48M$28.16M$33.80M$32.29MUnavailable$39.21M$41.64M$39.98M$39.67M$41.45M
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable$30.30M$25.14M$31.15MUnavailableUnavailable
Goodwill$13.88M$13.88M$13.88M$13.88MUnavailable$13.88M$13.88M$13.88M$13.88M$13.88M
Long-term debt$155.07M$148.74M$135.95M$130.44MUnavailable$110.53M$105.54M$124.67M$96.34M$92.08M
Accounts payable$7.53M$7.01M$10.12M$8.22MUnavailable$14.97M$18.01M$16.33M$15.68M$19.02M

Cash flow

LIFECORE BIOMEDICAL, INC. \DE\ cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-09-302025-05-252025-02-232024-11-242024-08-252024-05-262024-02-252023-11-26
Operating cash flow-$2.19M$4.70M$1.76M$5.35MUnavailable-$6.14M-$613.00K$8.72M-$1.42M$1.29M
Capital expenditures$513.00K$1.12M$1.74M$2.10MUnavailable$2.44M$3.42M$2.71M$6.37M$4.26M
Investing cash flow-$513.00K-$1.12M-$1.74M-$2.10MUnavailable-$2.44M-$3.42M-$2.71M-$6.37M-$4.26M
Financing cash flow-$852.00K-$256.00K-$1.39M-$402.00KUnavailable$12.52M$1.09M-$614.00K$7.64M-$2.45M
Net change in cash-$3.55M$3.33M-$1.36M$2.85MUnavailable$3.94M-$2.94M$5.39M-$148.00K-$5.42M
Stock-based compensation$2.08M$1.70M$2.39M$1.82MUnavailable$3.37M$2.42M$1.60M$1.49M$1.58M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable$1.98MUnavailableUnavailable$2.04M$1.99M$2.01M$2.01M$1.99M

Derived

LIFECORE BIOMEDICAL, INC. \DE\ derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-09-302025-05-252025-02-232024-11-242024-08-252024-05-262024-02-252023-11-26
Free cash flow-$2.70M$3.58M$25.00K$3.25MUnavailable-$8.58M-$4.04M$6.00M-$7.78M-$2.97M
Gross margin35.3%19.2%25.0%38.4%Unavailable34.0%21.8%45.6%33.3%33.0%
Operating margin7.5%-20.1%-9.9%14.6%Unavailable-6.0%-46.9%5.7%-2.5%-4.9%
FCF margin-7.9%15.4%0.1%8.9%Unavailable-26.3%-16.3%15.8%-21.8%-9.9%
SBC / revenue6.1%7.3%7.7%5.0%Unavailable10.4%9.8%4.2%4.2%5.2%
Current ratio3.87x3.79x2.80x2.84xUnavailable2.32x1.83x2.08x2.07x1.91x
Revenue YoY growthUnavailableUnavailableUnavailable-3.8%Unavailable8.0%0.7%21.6%34.5%37.9%
Net margin-18.0%-64.6%-32.1%-3.1%Unavailable-20.2%-65.7%-18.7%43.8%47.2%
R&D / revenue4.5%5.2%6.3%5.8%Unavailable5.9%8.8%5.7%6.1%7.0%
CapEx / revenue1.5%4.8%5.6%5.8%Unavailable7.5%13.9%7.2%17.8%14.1%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable1.4%-0.5%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LFCR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-K · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-04-03View SEC filing
10-Q · Filed 2025-01-02View SEC filing

Companies in the same industry

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2025-02-23

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-02-23

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-08-28

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2022-08-28

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.